rVSV(MΔ51)-M3 is an effective and safe oncolytic virus for cancer therapy

Human Gene Therapy

Volumn 19, Issue 6, 2008, Pages 635-647

  Wu, Lan ^a   Huang, Tian Gui ^a   Meseck, Marcia ^a   Altomonte, Jennifer ^a,b   Ebert, Oliver ^a,b   Shinozaki, Katsunori ^a,c   García Sastre, Adolfo ^a   Fallon, John ^a   Mandeli, John ^a   Woo, Savio L C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c HIROSHIMA PREFECTURAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; BINDING PROTEIN; CHEMOKINE; PROTEIN M3; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; GENE EXPRESSION; HEPATIC ARTERY; HERPES VIRUS; HERPES VIRUS 68; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIVER CELL CARCINOMA; MALE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; RAT; TREATMENT RESPONSE; TUMOR NECROSIS; VESICULAR STOMATITIS VIRUS; VIRUS RECOMBINANT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; CYTOKINES; GENETIC VECTORS; KILLER CELLS, NATURAL; LEUKOCYTE REDUCTION PROCEDURES; LIVER NEOPLASMS; LYMPHOCYTE DEPLETION; MALE; NEUTROPHILS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RATS; RATS, INBRED BUF; SEQUENCE DELETION; VESICULOVIRUS; VIRAL PROTEINS;

ANIMALIA; MURINAE; RATTUS; VESICULAR STOMATITIS VIRUS;

EID: 46249128028     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2007.163     Document Type: Article

References (65)

1. Ahmed, M., McKenzie, M.O., Puckett, S., Hojnacki, M., Poliquin, L., and Lyles, D.S. (2003). Ability of the matrix protein of VSV to suppress β interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J. Virol. 77, 4646-4657.
2. Alcami, A. (2003). Viral mimicry of cytokines, chemokines, and their receptors. Nat. Immunol. 3, 36-50.
3. Altomonte, J., Wu, L., Chen, L., Meseck, M., Ebert, O., García-Sastre, A., Fallon, J., and Woo, S.L. (2008). Exponential enhancement of oncolytic VSV potency by vector-mediated suppression of inflammatory responses in vivo. Mol. Ther. 16, 146-153.
4. Baggiolini, M. (1998). Chemokines and leukocyte traffic. Nature 392, 565-568.
5. Baraz, L., Khazanov, E., Condiotti, R., Kotler, M., and Nagler, A. (1999). Natural killer (NK) cells prevent virus production in cell culture. Bone Marrow Transplantation 24, 179-189.
6. Benencia, F., Courreges, M.C., Conejo-Garcia, J.R., Buckanovich, R.J., Zhang, L., Carroll, R.H., Morgan, M.A., and Coukos, G. (2005). Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. Hum. Gene Ther. 16, 765-778.
7. Bi, Z., and Reiss, C.S. (1995). Inhibition of vesicular stomatitis virus infection by nitric oxide. J. Virol. 69, 2208-2213.
8. Bi, Z., Barna, M., Komatsu, T., and Reiss, C.S. (1995). Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity. J. Virol. 69, 6466-6472.
9. Biron, C.A., and Brossay, L. (2001). NK cells and NKT cells in innate defense against viral infections. Curr. Opin. Immunol. 13, 458-464.
10. Biron, C.A., Nguyen, K.B., Pien, G.C., Cousens, L.P., and Salazar-Mather, T.P. (1999). Natural killer cells in antiviral defense: Function and regulation by innate cytokines. Annu. Rev. Immunol. 17, 189-220.
11. Breitbach, C.J., Paterson, J.M., Lemay, C.G., Falls, T.J., McGuire, A., Parato, K.A., Stojdl, D.F., Daneshmand, M., Speth, K., Kirn, D., McCart, J.A., Atkins, H., and Bell, J.C. (2007). Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther. 15, 1686-1693.
12. Brutkiewicz, R.R., and Welsh, R.M. (1995). Major histocompatibility complex class I antigens and the control of viral infections by natural killer cells. J. Virol. 69, 3967-3971.
13. Bryant, N.A., Davis-Poynter, N., Vanderplasschen, A.L., and Alcami, A. (2003). Glycoprotein G isoforms from some alpha-herpesviruses function as broad-spectrum chemokine binding proteins. EMBO J. 22, 833-846.
14. Cassatella, M.A. (1995). The production of cytokines by polymorphonuclear neutrophils. Immunol. Today 16, 21-26.
15. Chen, N., Restivo, A., and Reiss, C.S. (2001). Leukotrienes play protective roles early during experimental VSV encephalitis. J. Neuroimmunol. 120, 94-102.
16. Christian, A.Y., Barna, M., Bi, Z., and Reiss, C.S. (1996). Host immune response to vesicular stomatitis virus infection of the central nervous system in C57BL/6 mice. Viral Immunol. 9, 195-205.
17. Douglas, R.G., Jr., Alford, R.H., Cate, T.R., and Couch, R.B. (1966). The leukocyte response during viral respiratory illness in man. Ann. Intern. Med. 64, 521-530.
18. Ebert, O., Shinozaki, K., Huang, T.G., Savontaus, M.J., Garcia-Sastre, A., and Woo, S.L.C. (2003). Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res. 63, 611-613.
19. Ebert, O., Shinozaki, K., Kournioti, C., Park, M.S., García- Sastre, A., and Woo, S.L. (2004). Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res. 64, 3265-3270.
20. Ebert, O., Harbaran, S., Shinozaki, K., and Woo, S.L.C. (2005). Systemic therapy of experimental breast cancer metastases by mutant VSV in immune-competent mice. Cancer Gene Ther. 12, 350-358.
21. Faden, H., Hong, J.J., and Ogra, P.L. (1984). Interaction of polymorphonuclear leukocytes and viruses in humans: Adherence of polymorphonuclear leukocytes to respiratory syncytial virus-infected cells. J. Virol. 52, 16-23.
22. Feigin, R.D., and Shackelford, P.G. (1973). Value of repeat lumbar puncture in the differential diagnosis of meningitis. N. Engl. J. Med. 289, 571-574.
23. Ferran, M.C., and Lucas-Lenard, J.M. (1997). The VSV matrix protein inhibits transcription from the human β interferon promoter. J. Virol. 71, 371-377.
24. Fulci, G., Dmitrieva, N., Gianni, D., Fontana, E.J., Pan, X., Lu, Y., Kaufman, C.S., Kaur, B., Lawler, S.E., Lee, R.J., Marsh, C.B., Brat, D.J., van Rooijen, N., Stemmer-Rachamimov, A.O., Hochberg, F.H., Weissleder, R., Martuza, R.L., and Chiocca, E.A. (2007). Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res. 67, 9398-9406.
25. Gaddy, D.F., and Lyles, D.S. (2005). Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J. Virol. 79, 4170-4179.
26. Ganz, T., Selsted, M.E., Szklarek, D., Harwig, S.S., Daher, K., Bainton, D.F., and Lehrer, R.I. (1985). Defensins: Natural peptide antibiotics of human neutrophils. J. Clin. Invest. 76, 1427-1435.
27. Hashimoto, G., Wright, P.F., and Karzon, D.T. (1983). Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J. Infect. Dis. 148, 785-794.
28. Huneycutt, B.S., Bi, Z., Aoki, C.J., and Reiss, C.S. (1993). Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice. J. Virol. 67, 6698-6706.
29. Ihara, T., Starr, S.E., Ito, M., Douglas, S.D., and Arbeter, A.M. (1984). Human polymorphonuclear leukocyte-mediated cytotoxicity against varicella-zoster virus-infected fibroblasts. J. Virol. 51, 110-116.
30. Ikeda, K., Ichikawa, T., Wakimoto, H., Silver, J.S., Deisboeck, T.S., Finkelstein, D., Harsh, G.R., IV, Louis, D.N., Bartus, R.T., Hochberg, F.H., and Chiocca, E.A. (1999). Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 5, 881-887.
31. Ikeda, K., Wakimoto, H., Ichikawa, T., Jhung, S., Hochberg, F.H., Louis, D.N., and Chiocca, E.A. (2000). Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J. Virol. 74, 4765-4775.
32. Ireland, D.D., and Reiss, C.S. (2006). Gene expression contributing to recruitment of circulating cells in response to vesicular stomatitis virus infection of the CNS. Viral Immunol. 19, 536-545.
33. Kurozumi, K., Hardcastle, J., Thakur, R., Yang, M., Christoforidis, G., Fulci, G., Hochberg, F.H., Weissleder, R., Carson, W., Chiocca, E.A., and Kaur, B. (2007). Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J. Natl. Cancer Inst. 99, 1768-1781.
34. Lalani, A.S., and McFadden, G. (1997). Secreted poxvirus chemokine binding proteins. J. Leukoc. Biol. 62, 570-576.
35. Lawson, N.D., Stillman, E.A., Whitt, M.A., and Rose, J.K. (1995). Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. U.S.A. 92, 4477-4481.
36. Lloyd, A.R., and Oppenheim, J.J. (1992). Poly's lament: The neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response. Immunol. Today 13, 169-172.
37. Luster, A.D. (1998). Chemokine-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338, 436-445.
38. MacDonald, M.R., Li, X.Y., and Virgin, H.W., IV. (1997). Late expression of a β chemokine homolog by murine cytomegalovirus. J. Virol. 71, 1671-1678.
39. MacGregor, R.B., Friedman, H.M., Macarak, E.J., and Kefalides, N.A. (1980). Virus infection of endothelial cells increases granulocyte adherence. J. Clin. Invest. 65, 1469-1477.
40. Marcus, P.I., Rodriguez, L.L., and Sekellick, M.J. (1998). Interferon induction as a quasispecies marker of VSV populations. J. Virol. 72, 542-549.
41. Mollinedo, F., Borregaard, N., and Boxer, L.A. (1999). Novel trends in neutrophil structure, function, and development. Immunol. Today 20, 535-537.
42. Orange, J.S., Fassett, M.S., Koopman, L.A., Boyson, J.E., and Strominger, J.L. (2002). Viral evasion of natural killer cells. Nat. Immunol. 3, 1006-1012.
43. Parry, C.M., Simas, J.P., Smith, V.P., Stewart, C.A., Minson, A.C., Efstathiou, S., and Alcami, A. (2000). A broad spectrum secreted chemokine binding protein encoded by a herpesvirus. J. Exp. Med. 191, 573-578.
44. Penfold, M.E., Dairaghi, D.J., Duke, G.M., Duke, N., and Saedeup, E.S. (1999). Cytomegalovirus encodes a potent Proc. Natl. Acad. Sci. chemokine. Proc. Natl. Acad. Sci. U.S.A. 96, 9839-9844.
45. Petersen, J.M., Her, L.S., Varvel, V., Lund, E., and Dahlberg, J.E. (2000). The matrix protein of VSV inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes. Mol. Cell. Biol. 20, 8590-8601.
46. Ratcliffe, D.R., Nolin, S.L., and Cramer, E.B. (1988). Neutrophil interaction with influenza-infected epithelial cells. Blood 72, 142-149.
47. Rogers, H.W., and Unanue, E.R. (1993). Neutrophils are involved in acute, nonspecific resistance to Listeria monocytogenes in mice. Infect. Immun. 61, 5090-5096.
48. Rollins, B.J. (1997). Chemokines. Blood 90, 909-928.
49. Schall, T.J., and Bacon, K.B. (1994). Chemokines, leukocyte trafficking, and inflammation. Curr. Opin. Immunol. 6, 865-873.
50. Schneider-Schaulies, J. (2000). Cellular receptors for viruses: Links to tropism and pathogenesis. J. Gen. Virol. 81, 1413-1429.
51. Seet, B., and McFadden, G. (2002). Viral chemokine-binding proteins. J. Leukoc. Biol. 72, 24-34.
52. Shinozaki, K., Ebert, O., Suriawinata, A., Thung, S.N., and Woo, S.L. (2005). Prophylactic α interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats. J. Virol. 79, 13705-13713.
53. Siebens, H., Tevethia, S.S., and Babior, B.M. (1979). Neutrophil-mediated antibody-dependent killing of herpes-simplex-virus-infected cells. Blood 54, 88-94.
54. Smith, J.A. (1994). Neutrophils, host defense, and inflammation: A double-edged sword. J. Leukoc. Biol. 56, 672-686.
55. Stojdl, D.F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., and Bell, J.C. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6, 821-825.
56. Stojdl, D.F., Lichty, B.D., tenOever, B.R., Paterson, J.M., Power, A.T., Knowles, S., Marius, R., Reynard, J., Poliquin, L., Atkins, H., Brown, E.G., Durbin, R.K., Durbin, J.E., Hiscott, J., and Bell, J.C. (2003). VSV strain with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4, 263-275.
57. Thomas, D.L., and Fraser, N.W. (2003). HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer. Mol. Ther. 8, 543-551.
58. Todo, T., Martuza, R.L., Rabkin, S.D., and Johnson, P.A. (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. U.S.A. 98, 6396-6401.
59. Trinchieri, G. (1989). Biology of natural killer cells. Adv. Immunol. 47, 187.
60. Tsuru, S., Fujisawa, H., Taniguchi, M., Zinnaka, Y., and Nomoto, K. (1987). Mechanism of protection during the early phase of a generalized viral infection. II. Contribution of polymorphonuclear leukocytes to protection against intravenous infection with influenza virus. J. Gen. Virol. 68, 419-424.
61. van Berkel, V., Barrett, J., Tiffany, H.L., Fremont, D.H., Murphy, P.M., McFadden, G., Speck, S.H., and Virgin, H.W., IV. (2000). Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J. Virol. 74, 6741-6747.
62. van den Pol, A.N., Dalton, K.P., and Rose, J.K. (2002). Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J. Virol. 76, 1309-1327.
63. von Kobbe, C., van Deursen, J.M., Rodrigues, J.P., Sitterlin, D., Bachi, A., Wu, X., Wilm, M., Carmo-Fonseca, M., and Izaurralde, E. (2000). VSV matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98. Mol. Cell. 6, 1243-1252.
64. Welsh, R.M. (1986). Regulation of virus infections by natural killer cells. Nat. Immun. Cell Growth Regul. 5, 169-199.
65. Whelan, S.P., Ball, L.A., Barr, J.N., and Wertz, G.T. (1995). Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc. Natl. Acad. Sci. U.S.A. 92, 8388-8392.